Drug Shortage Management in Clinical Trials: Strategies for Sponsors in 2026
A trial can have perfect science. It can still stall on supply. That’s the quiet risk in 2026.
Drug shortages are rising again. For sponsors, that means comparator risk. It means rescue medication risk. It means timeline risk nobody budgeted for.
Here’s what the data shows. And here’s how sponsors can respond.
Where Drug Shortages Stand in 2026
The numbers moved gently, then steadily. Active US shortages hit 227 in Q2 2026. That’s the third straight quarterly rise. The all-time peak was 323, in early 2024.
There’s a nuance worth noting. New shortages fell to 89 in 2025. That’s the lowest yearly total since 2006. Yet three in four active shortages started in 2022 or later.
So fewer new problems appear. But old ones rarely resolve fully.
Why Clinical Trials Feel It First
Trials need exact products. Same strength, same presentation, same source. Substitution isn’t simple in a protocol.
Three trends make this sharper:
↳ Sole-source dependency. Nearly half of 2026’s new shortages involve one manufacturer.
↳ Oncology exposure. Ifosfamide entered severe shortage this year. Quality issues at a key supplier caused it.
↳ Controlled substance pressure. 16% of active shortages are controlled substances.
Each one touches common trial designs. Oncology comparators. Background therapies. Rescue and supportive medications.
Europe Is Responding Too
The EU is acting on supply resilience. A Critical Medicines Act deal came on 12 May 2026. It’s still awaiting formal adoption. The Union’s 2026 critical list holds around 300 medicines.
For global sponsors, this matters. EU procurement priorities may shift. Supply planning should reflect both regions.
Five Strategies for Sponsors in 2026
1. Screen Shortage Risk at Protocol Design
Check every comparator early. Check background and rescue drugs too. Use ASHP and FDA shortage databases. Flag sole-source products before finalising the protocol.
2. Qualify More Than One Source
One supplier is a single point of failure. Build a second qualified channel early. Consider multiple approved markets where protocols allow. Document equivalence decisions with your regulatory team.
3. Forecast with Buffer, Not Hope
Enrollment rarely follows the plan. Model best, expected and slow scenarios. Hold safety stock for critical products. Review forecasts at every enrollment milestone.
4. Secure Batches and Expiry Early
Shortages often tighten long-dated stock first. Reserve batches with adequate shelf life. Align expiry with your study duration. Plan re-supply before stock runs low.
5. Build a Written Contingency Plan
Don’t wait for the first delay. Define triggers that activate backup sourcing. Name decision owners in advance. Pre-agree alternative sourcing paths with partners.
A plan made calmly works better. Decisions made under pressure cost more.
Signs Your Trial Supply Is at Risk
Watch for these early signals:
↳ Longer lead times from your supplier
↳ Allocation limits on orders
↳ Only short-dated batches available
↳ New listings on shortage databases
↳ Quality notices at manufacturing sites
Catching them early buys valuable weeks.
How NewLife Medicals Supports Sponsors During Shortages
Contingency needs a partner with reach. NewLife Medicals works across 35+ countries. We hold licensed facilities in North Carolina. Our EU base sits in Dublin, Ireland.
That network gives sponsors options:
↳ Multi-market sourcing of comparators and RLDs
↳ Alternative supply channels when markets tighten
↳ Batch and expiry planning for trial duration
↳ Temperature-controlled global logistics
↳ Full documentation and chain of custody
We don’t promise shortages won’t happen. We help you stay ready when they do.
Final Thoughts
Shortages are part of 2026’s reality. They don’t have to delay your trial. Early screening lowers exposure. Dual sourcing adds resilience. A clear plan keeps teams calm.
Supply security is now trial strategy.
Facing a comparator or supply gap? Talk to the NewLife Medicals sourcing team. Start at newlifemedicals.com.
Frequently Asked Questions
Through early risk screening and dual sourcing. Buffer forecasting and contingency plans help too.
Activate backup sourcing channels quickly. Involve regulatory teams on any source change.
Use the FDA Drug Shortages Database. ASHP also tracks shortages nationally.
